A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Phase 2
100
about 3.3 years
18+
Male only
4 sites in CA, IA, NY +1
What this study is about
This trial is testing a treatment called inavolisib, combined with enzalutamide, compared to other treatments like docetaxel or an alternative androgen receptor pathway inhibitor (ARPi), in men with metastatic castrate-resistant prostate cancer who have already received one prior second-generation ARPi. The goal of this trial is to see if this new treatment combination improves outcomes and safety for these patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.FoundationOne® CDx (F1CDx) Assay
- 2.Take Abiraterone
- 3.Take Docetaxel
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
abiraterone, docetaxel, enzalutamide, Antineoplastic Agent [TC] (Phosphoinositide 3-Kinase alpha Inhibitors)
infusion, oral (Oral Tablet)
Primary: Radiographic Progression-free Survival (rPFS)
Secondary: Duration of Response (DOR), Objective Response Rate (ORR), Overall Survival (OS), Percentage of Participants With Adverse Events (AEs), Percentage of Participants with Confirmed Composite Response Rate (RR)
Oncology